Knowledge Library
Targeted Protein Degradation
WuXi AppTec utilizes state-of-the-art techniques to support drug discovery teams focused on targeted protein degradation. Our services include a broad range of ligand-finding methods, such as DEL, fragment screening, ASMS, and virtual screening. We provide custom linker design and complex synthesis for new linkers and E3 ligase ligands. To support lead optimization efforts, our platform …Read More >
Biological Characterization and Development Workflows for Targeted Protein Degradation
This webinar will focus on PROTAC biology workflows, such as in vitro screening assays, in vivo testing, and optimization of DMPK properties. Topics will include the best use of biochemical assays to measure binary/ternary complex formation, cell-based assays to assess target engagement and degradation, strategies for enhancing drug delivery and formulation, and PK/PD evaluation of …Read More >
OncoWuXi Newsletter December 2022
WuXi AppTec in vitro Neuroscience Services
Neurological disorders, such as neurodegenerative diseases, epilepsy, chronic pain, psychiatric disorders, are one of today’s largest unmet medical needs. However, due to poor disease and target understanding, Neuroscience drug discovery can be very challenging. An open access research platform with dedicated neuroscience specialists and integrated services will be an ideal partner throughout your drug discovery …Read More >
How Does It Work? | Peptide-Oligonucleotide Conjugates
This week’s episode of our “How Does It Work?” series features Peptide-Oligonucleotide Conjugates. Peptide-oligonucleotide conjugates are made up of peptide and oligonucleotide components. These cutting-edge molecules have many applications in biomedicine. The oligonucleotide component can interact with mRNA to alter gene expression within diseased cells but oligonucleotides are easily degraded in the body and have …Read More >
How Does It Work? | Antibody Drug Conjugates
In this week’s installment of our “How Does It Work?” video series, we explore Antibody Drug Conjugates. Monoclonal antibodies are highly versatile molecules that we can modify to generate new and improved cancer therapies. Here we have a type of modified antibody, known as an antibody drug conjugate, or ADC. The ADC contains two antigen …Read More >
WuXi AppTec Oligonucleotide Biology Platform
We offer a wide range of oligonucleotide services, including: Sequence design Knockdown effect in cell lines and primary cells Splicing analysis Functional assays and assessment of off-target effects Transgenic, HDI and AAV mouse models GalNAc-ASGPR delivery system and customized assays for other delivery systems Stability and protein-protein binding assays Delivery/RISC PK in mouse, rat, and …Read More >
How Does It Work? | Targeted Protein Degrader
As part of our dedication to providing an #openaccess platform, so our entire ecosystem can come together to share #science & #collaborate to better the lives of all #patientsfirst. We’ve created MoA animations in our new series exploring biotech topics on a molecular level. First up, we explain the intricacies of how targeted protein degradation …Read More >
Oligonucleotide Drug Discovery
Recent years have seen a huge surge of interest in oligonucleotide therapeutics, fueled by major advances in our understanding of how to make such molecules stable, selective, and efficient as drug modalities. The field is now diverse in terms of therapeutic areas being addressed, biological processes being manipulated and delivery technologies employed. In this webinar, …Read More >